Chile's "domestic Ozempic" claims: what the evidence actually shows

What did @meganoticias.cl actually say?

The caption, not the spoken transcript, carries the real claim here: that health experts have confirmed a domestically manufactured injectable version of Ozempic exists in Chile, with "similar effects" to the original product but at a significantly lower cost. The actual spoken audio is largely unintelligible, referencing "STEM," "Indicacion," "Valvacian," and "Peron professional America" in fragmented form. The substantive claim lives entirely in the text overlay and caption, not in any coherent expert testimony from the video itself.

That distinction matters. A 2.5 million-view video making drug equivalency claims while the spoken content is garbled is a red flag, not a green light. Viewers are reading a health claim that the video never actually substantiates out loud.

Does the science back this up?

Partly, but with serious caveats the video ignores entirely. Semaglutide, the active compound in Ozempic and Wegovy, is not under patent protection in all markets, and compounded or biosimilar versions do exist in various countries. What the video skips is that "similar effects" is doing enormous heavy lifting in that sentence.

A 2023 paper by Smits and Van Raalte in Diabetes Care noted that even small formulation differences in GLP-1 receptor agonists, including excipients, delivery mechanisms, and concentration, can affect tolerability and pharmacokinetics. The FDA's own 2024 guidance on compounded semaglutide products explicitly stated that compounded drugs are not FDA-approved and have not been shown to be safe and effective in the same way as the reference listed drug. Chile's Instituto de Salud Pública (ISP) has similar registration requirements. Whether a domestic Chilean product has cleared those hurdles is not addressed anywhere in this video.

What did they get wrong (or right)?

They got one thing directionally right: lower-cost alternatives to brand-name semaglutide are a legitimate and important public health conversation. Ozempic costs upward of $900 per month in the U.S. without insurance, and pricing pressure in Latin American markets is real. That framing deserves credit.

What they got wrong is consequential. Calling something a "version" of Ozempic with "similar effects" implies therapeutic equivalency. It does not exist in any regulatory sense unless a product has completed bioequivalence studies and received approval from the relevant authority. No such evidence is cited. The FDA in 2024 specifically warned that some compounded semaglutide products have been associated with dosing errors and adverse events due to concentration differences. Presenting a cost-friendly copy as basically the same drug, without any regulatory or clinical context, is misleading, full stop. The video also cites unnamed "health experts," which is not a citation.

What should you actually know?

If you are considering a lower-cost semaglutide product, the relevant questions are not just about price. You need to know whether the product is registered with your country's drug regulatory authority, whether it has completed bioequivalence or pharmacokinetic studies, and whether the prescribing physician is monitoring you with the same protocols used in the SUSTAIN and STEP clinical trials that established semaglutide's safety profile.

Compounded or biosimilar GLP-1 products are not inherently dangerous, but they are not interchangeable with brand-name drugs by default. A 2022 review by Grabowski et al. in Health Affairs found that biosimilar uptake in Latin America varied widely based on regulatory stringency, and that not all products marketed as biosimilars met the same evidentiary standards. Talk to a licensed clinician before switching or starting any semaglutide product, regardless of where it is manufactured or what it costs.